Clinical Trials Directory

Trials / Unknown

UnknownNCT01620749

Of 18F MEL050 Using PET/CT in Metastatic Melanoma

A Phase 0 Exploratory Microdosing Study of 6-18fluoro-N-[2-(Diethylamino)Ethyl]Pyridine-3-carboxamide (18F MEL050) Using PET/CT in Patients With Metastatic Melanoma

Status
Unknown
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Cooperative Research Centre for Biomedical Imaging Development · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F MEL050 for finding sites of melanoma.

Conditions

Interventions

TypeNameDescription
RADIATION18F MEL050Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.

Timeline

Start date
2010-06-01
Primary completion
2012-03-01
Completion
2012-12-01
First posted
2012-06-15
Last updated
2012-06-15

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT01620749. Inclusion in this directory is not an endorsement.

Of 18F MEL050 Using PET/CT in Metastatic Melanoma (NCT01620749) · Clinical Trials Directory